As of Q3'25, RXRX's ROS (Return on Sales) stands at -31.35%, reflecting a significant deterioration from the previous quarter's -8.94%. This latest data point indicates a sharp decline in profitability for the most recent period reported. Over the period from Q1'23 to Q3'25, RXRX's ROS has exhibited considerable volatility, with values consistently negative throughout. After reaching a low of -8.91% in Q4'23, the metric briefly improved to -3.67% in Q3'24 before plunging to -39.35% in Q4'24. Despite a partial recovery in Q1'25 and Q2'25, the ROS remains deeply negative, highlighting ongoing profitability challenges and significant fluctuations in operating performance across the observed quarters.